KPI data tables
Arcturus Therapeutics operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Cash and cash equivalents |
|---|---|
| Q3 2026 | 184.817 |
| Q2 2026 | 191.483 |
| Q1 2026 | 211.375 |
| Q4 2025 | 230.909 |
| Q3 2025 | 180.36 |
| Q2 2025 | 196.467 |
| Q1 2025 | 216.948 |
| Q4 2024 | 237.028 |
| Q3 2024 | 237.178 |
| Q2 2024 | 260.329 |
| Q1 2024 | 288.396 |
| Q4 2023 | 292.005 |
Source: Arcturus cash and cash equivalents, balance sheet (thousands, charted as millions). Q3 2026 10-Q (filed 2026-11-05, https://www.sec.gov/Archives/edgar/data/1768224/000119312526449901/arct-20260930.htm): $184,817 at 30 Sep 2026 and $180,360 at 30 Sep 2025. Q2 2026 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312526338090/arct-20260630.htm): $191,483 at 30 Jun 2026 and $196,467 at 30 Jun 2025; restricted-cash reconciliation. Q1 2026 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312526211943/arct-20260331.htm): $211,375 at 31 Mar 2026 and $216,948 at 31 Mar 2025. FY2025 10-K (https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/arct-20251231.htm): $230,909 at 31 Dec 2025 and $237,028 at 31 Dec 2024. Q3 2025 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312525275758/arct-20250930.htm): $180,360 at 30 Sep 2025 and $237,178 at 30 Sep 2024. Q2 2025 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000095017025106560/arct-20250630.htm): $260,329 at 30 Jun 2024. Q1 2024 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000095017024055702/arct-20240331.htm): $288,396 at 31 Mar 2024 and $292,005 at 31 Dec 2023. Runway floor: Q2 2026 Exhibit 99.1 (https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_ex99-1.htm). ATM: Q2 2026 10-Q Note 5.
| Period | LUNAR-COVID | LUNAR-OTC | BARDA | LUNAR-CF, net | Early-stage programs | Discovery technologies | Payroll and benefits | Facilities and equipment |
|---|---|---|---|---|---|---|---|---|
| Q3 2026 | 1.115 | 3.073 | 0 | 2.042 | 0 | 1.747 | 7.345 | 1.676 |
| Q2 2026 | 0.391 | 1.87 | 0.642 | 2.593 | 0.092 | 1.341 | 8.731 | 1.855 |
| Q1 2026 | 0.602 | 2.718 | 0.324 | 6.531 | 0.243 | 1.754 | 7.619 | 1.736 |
| Q4 2025 | 2.585 | 0.491 | 2.383 | 2.502 | 0.058 | 1.67 | 10.64 | 4.147 |
| Q3 2025 | 3.89 | 0.78 | 1.043 | 3.21 | 0.37 | 1.72 | 9.693 | 2.559 |
| Q2 2025 | 3.831 | 2.901 | 2.459 | 4.629 | 0.167 | 2.439 | 10.611 | 2.542 |
| Q1 2025 | 5.809 | 1.576 | 2.481 | 7.148 | 0 | 2.187 | 13.043 | 2.649 |
Source: Arcturus Form 10-Q / 10-K segment R&D tables (thousands, charted as millions). Q1 2025 and Q1 2026: Q1 2026 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312526211943/arct-20260331.htm). Q2 2025 and Q2 2026: Q2 2026 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312526338090/arct-20260630.htm). Q3 2026 (three months ended 30 Sep 2026; BARDA and early-stage programs printed as dashes, charted as 0): Q3 2026 10-Q, filed 2026-11-05 (https://www.sec.gov/Archives/edgar/data/1768224/000119312526449901/arct-20260930.htm). Q3 2025: Q3 2025 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312525275758/arct-20250930.htm). Q4 2025: FY2025 10-K (https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/arct-20251231.htm) annual totals minus Q3 2025 nine-month totals.